Vutrisiran ATTR Cm denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Step Therapy to Vutrisiran (ATTR-CM) — and How to Appeal

Vutrisiran (Amvuttra) is FDA-approved for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). Cigna's coverage policy may require documented use of — and inadequate response to or intolerance of — one or more other approved ATTR therapies before authorizing vutrisiran. This is step therapy (also called "fail-first"). The denial indicates that Cigna's reviewer determined the submitted documentation did not demonstrate completion of the required steps or that a clinical exception applies.

## Why This Denial Is Appealable

Step-therapy requirements must be medically sound and must account for exceptions. Under ACA §2719, you have the right to a full internal appeal and then an independent external review. Under ERISA §503 (for employer-sponsored plans), a full-and-fair review is required. Many states have enacted step-therapy exception laws that prohibit requiring patients to retry therapies they have already failed, cannot tolerate, or that a physician determines are clinically inappropriate. The external-review window is typically available for approximately four months after a final internal denial, and expedited review (often resolved within 72 hours) is available when delay would seriously jeopardize your health.

For ATTR-CM — a condition in which disease progression during a coverage gap is irreversible — the urgency argument for expedited review is particularly strong.

## What to Gather

• Diagnosis and disease progression records: Cardiologist notes, nuclear imaging, echocardiography, or other cardiac assessments documenting ATTR-CM diagnosis, subtype, and current functional status.
• Prior-therapy documentation: For each therapy Cigna's policy requires as a prior step, provide: the drug name, start date, duration, reason for discontinuation or transition, and documented clinical outcome. If a prior therapy was not tried because it was clinically inappropriate for your case, document that reason explicitly.
• Step-therapy exception basis: If an exception applies (prior failure, contraindication, or physician-determined clinical inappropriateness), document it clearly with chart evidence and a prescriber letter.
• Prescriber medical-necessity letter: A letter from your cardiologist explaining the clinical rationale for vutrisiran at this stage of your treatment history, referencing the FDA-approved labeling and applicable ACC/AHA guidance.
• Cigna's step-therapy policy: Request the exact written criteria so your appeal addresses each required step and any available exception pathway.

## Criteria-Mapping Structure

For each required step in Cigna's policy, provide a direct evidentiary response:

> Cigna required step: [paste verbatim] > Chart evidence of completion or exception: [drug name, dates, outcome, or physician note explaining why the step was completed, failed, or is subject to exception]

## Timeline

File your internal appeal immediately — confirm the exact deadline in your denial letter. Request expedited review in writing given the progressive nature of ATTR-CM. After a final internal denial, file for external review promptly to preserve your rights within the approximately four-month window.